A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Insulin degludec/insulin aspart (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 03 Oct 2016 Status changed from recruiting to completed.
- 06 Sep 2016 Status changed from not yet recruiting to recruiting.
- 28 Jul 2016 New trial record